Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W. Ostrominski, Muthiah Vaduganathan, Mikhail Kosiborod et al.|JACC Heart Failure|2023Cited by 39
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan et al.|European Journal of Heart Failure|2022Cited by 32
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan et al.|Circulation|2023Cited by 20